Participated · Series B · Jul 2026

Draig Therapeutics is a clinical-stage biopharma focused on developing highly specific AMPA receptor (AMPAR) and GABAA receptor (GABAAR) modulators aimed at treating neuropsychiatric disorders. Its lead program, DT-101, is a Phase 2 AMPAR positive allosteric modulator (PAM) being evaluated in major depressive disorder in a global monotherapy study and a U.S. adjunct study. The company states DT-101 has shown encouraging safety, tolerability and target engagement with a pulsatile pharmacokinetic profile. Draig was co-founded by Cardiff University and SV Health Investors and is backed by venture investors including Access Biotechnology, Canaan Partners, SR One, Sanofi Ventures and Schroders Capital. Following the oversubscribed $65 million Series B, the company plans to use proceeds to accelerate clinical development across its pipeline and advance additional candidates toward the clinic.

Participated · Series B · Apr 2026

Ray Therapeutics is a Berkeley, California–based clinical-stage biopharmaceutical company developing optogenetic gene therapies to restore vision in patients with severe retinal degenerations. Its lead program, RTx-015, is an optogenetic gene therapy delivered as a single intravitreal injection and is being evaluated in patients with retinitis pigmentosa. The company’s second clinical-stage program, RTx-021, targets retinal bipolar cells and is designed for macular diseases such as Stargardt disease and geographic atrophy (GA AMD). RayTx’s approach delivers a bioengineered, highly light-sensitive protein to targeted retinal cells with the aim of improving visual function regardless of underlying genetic mutation. The company recently received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for RTx-015, and it plans to use recent financing to advance late-stage clinical development and commercial readiness.

Participated · Series A · Feb 2026

Third Arc Bio, launched in 2022, focuses on creating multispecific antibodies that form immune synapses to either activate or inhibit T cells with high precision. Its lead program, ARC101, is a bispecific T-cell engager targeting CLDN6 and is currently in Phase 1 dose-escalation studies for patients with advanced solid tumors. The company’s solid-tumor ARCStim platform and immunology-focused ARCTag (Tethered Agonist) platform underpin a broader pipeline aimed at both cancer and immune-mediated disorders. By localizing immune modulation to sites of disease, Third Arc seeks to improve both efficacy and safety over conventional systemic therapies. The management team includes executives with prior drug-development track records, and a16z General Partner Jorge Conde recently joined the board. Financially, Third Arc Bio has secured at least $217 million in Series A funding (an initial $165 million plus a $52 million extension) in addition to earlier seed capital. Proceeds are earmarked to accelerate its immunology portfolio and advance additional oncology programs into the clinic.

Participated · Series F · Jan 2026

Parabilis Medicines is pioneering stabilized, cell-penetrant α-helical peptides, called Helicons™, to modulate intracellular proteins that small molecules and antibodies cannot reach. Its lead candidate, FOG-001 (zolucatetide), directly inhibits the β-catenin:TCF interaction within the Wnt/β-catenin pathway and has shown meaningful single-agent activity across five tumor types, including desmoid tumors and adamantinomatous craniopharyngioma. The drug has U.S. FDA Fast Track Designation for desmoid tumors and is moving toward a registrational trial while additional data in hepatocellular carcinoma and familial adenomatous polyposis are forthcoming. Beyond FOG-001, Parabilis is advancing preclinical Helicon degraders against ERG and allosteric ARON for prostate cancer, demonstrating the broad applicability of its platform. Headquartered in Cambridge, Massachusetts, the company leverages proprietary data, AI- and physics-based algorithms, and more than a decade of laboratory innovation. Financially, Parabilis closed an oversubscribed $305 million Series F round at an increased valuation, positioning it to expand clinical and preclinical programs. No revenue or user metrics have been disclosed, consistent with its clinical-stage status.

Participated · Equity · Nov 2025

Ripple offers blockchain-based enterprise solutions spanning global payments, custody, liquidity, and treasury management. It operates a multi-asset prime brokerage platform called Ripple Prime that provides financing and other services to institutional clients in traditional and digital markets. Founded in 2012 and based in San Francisco, Ripple positions itself as a one-stop shop for moving, storing, exchanging, and managing value. The company has secured a $200M debt facility from funds managed by Neuberger Specialty Finance to support growth of Ripple Prime and extend client financing. The financing is intended to increase Ripple's capacity and enhance its ability to serve new and existing institutional relationships. The deal reflects Ripple's focus on expanding institutional-facing products and access to capital.